Bedfont wins FDA clearance for airway inflammation monitoring system

[Image from Bedfont Scientific]Bedfont Scientific announced today that it received FDA clearance for its NObreath FeNO airway inflammation monitor.

Maidstone, England-based Bedfont designed its NObreath fractional exhaled nitric oxide (FeNO) monitoring system as a portable, non-invasive device for measuring FeNO in human breath as the production of nitric oxide can often be increased in inflammatory conditions like asthma.

According to a news release, NObreath works by measuring FeNO through breath analysis in a quick, simple and non-invasive process. Measuring FeNO levels allows for the identification of patients who do or do not require ongoing treatment. It can also differentiate between allergic and non-allergic asthma and daily use can help to predict and prevent exacerbations and attacks, Bedfont said.

“NObreath has been available outside the US for over 12 years now, we have been working towards FDA clearance for quite some time and we are over…

Read more
  • 0